Journal article
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes
Abstract
BACKGROUND: Exploratory analysis of the phase 2 PACIFIC-Stroke (Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-Non-Cardioembolic Stroke) randomized trial suggested that asundexian, an oral factor XIa inhibitor, prevents recurrent stroke and transient ischemic attacks in patients with atherosclerotic stroke. In this post hoc exploratory analysis, we hypothesized that asundexian would be more effective in …
Authors
Smith EE; Shoamanesh A; Xu L; Heenan L; Saad F; Colorado P; Chen C-H; Lemmens R; De Marchis GM; Caso V
Journal
Stroke, Vol. 55, No. 2, pp. 392–402
Publisher
Wolters Kluwer
Publication Date
February 2024
DOI
10.1161/strokeaha.123.043198
ISSN
0039-2499